PRCM
TENX icon

Pine River Capital Management’s Tenax Therapeutics TENX Stock Holding History

Pine River Capital Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-16
Closed -$2.02M – 942
2014
Q3 		$2.02M Hold
16
– – 0.02% 459
2014
Q2 		$2.09M Sell
16
-1
-6% -$154K 0.03% 365
2014
Q1 		$3M Buy
+17
New +$3.37M 0.05% 336

Other funds holding TENX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Pine River Capital Management's TENX Position: Q4 2014 in Review

Pine River Capital Management sold out of Tenax Therapeutics (TENX) in Q4 2014, closing a stake of 16 shares — an estimated $2.02M sold.

Pine River Capital Management first reported a position in TENX in Q1 2014 and held it in 3 quarters. The position peaked at $3M in Q1 2014. 19 funds tracked by Wall St. Rank hold TENX as of Q4 2014.

  • Pine River Capital Management reported no remaining Tenax Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Pine River Capital Management sold 16 Tenax Therapeutics shares in Q4 2014, an estimated $2.02M.
  • Pine River Capital Management first reported a position in Tenax Therapeutics in Q1 2014 and held it in 3 quarters.
  • Pine River Capital Management's Tenax Therapeutics position peaked at $3M in Q1 2014.
  • 19 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q4 2014.

Based on Pine River Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.